Hospital Jerez de la Frontera
- Address
- lock Available on a paid plan
Oncology – Advanced Solid Tumors
The Hospital Jerez de la Frontera is conducting research focused on advanced solid tumors within the broader field of neoplasms. The studies aim to assess new combination therapies for safety, tolerability, and antitumor activity.
- Evaluation of safety and tolerability of novel drug combinations
- Identification of optimal dosing regimens through dose‑optimization studies
- Assessment of antitumor efficacy in patients with advanced cancers
With a team of 42 investigators, the site is advancing precision oncology by testing the investigational agent PF‑08634404 paired with partner compounds, seeking to improve outcomes for patients across Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 10 therapeutic areas and 15 of 254 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 234 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 38 by active trials.
- 1Janssen Cilag International7active
lock +37 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International14trials
lock +21 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Jerez de la Frontera
lock Showing 1 of 124 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-Week Randomized Double-Blind Trial Comparing CHF5993 (Beclometasone Dipropionate, Formoterol Fumarate, Glycopyrronium Bromide) to Fluticasone Propionate/Salmeterol in Adolescents with Uncontrolled Asthma | Chiesi Farmaceutici S.p.A. | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 254 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 10 | Unknown | 2024-03-20 | 2026-07-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.